Chugai Pharmaceutical revenue and financials
¥6,101.00Change from previous close: −0.31%Absolute change: −¥19.00
In the fiscal year ended December 2025, Chugai Pharmaceutical reported revenue of ¥1.26T (+7.46% year over year). Net income was ¥434.01B, a net margin of 34.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +7.46%
- 2025 vs 2024
- Net income growth
- +12.06%
- 2025 vs 2024
- Net margin
- 34.5%
- 2024: 33.1%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 386,280 | 447,600 | 409,925 | 243,582 | — |
| Capital expenditure | -111,607 | -54,899 | -74,258 | -71,239 | — |
| Investing cash flow | -201,273 | -227,365 | -37,290 | -145,465 | — |
| Financing cash flow | -307,886 | -141,006 | -139,331 | -145,641 | — |
| Dividends paid | -299,419 | -133,249 | -131,594 | -138,220 | — |
| Share repurchases | -6.0 | -10.0 | -5.0 | -5.0 | — |
| Effect of exchange rates | 9,279 | 2,299 | 3,202 | 1,939 | — |
| Net change in cash | -122,879 | 79,229 | 233,304 | -47,524 | — |
| Free cash flow | 274,673 | 392,701 | 335,667 | 172,343 | — |